Skip to main content

Table 1 Baseline characteristics of 47 patients followed-up in one center for a rheumatic disease necessitating DMARD and/or biologic therapy, and with definite bronchiectasis

From: Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases

 

All patients

(N = 47)

Rheumatoid Arthritis

(N = 40)

Others diagnosis (N = 7)

Mean age (SD) [range], years

64.1 (9.1) [38;78]

65.8 (7.9) [43;78]

54.4 (9.7) [38;67]

Sex N (%) female

33 (70.2)

30 (75.0)

3 (42.9)

Mean disease duration of rheumatic disease at first follow up (SD) [range], years

10.7 (8.8)

[1;43]

11.5 (8.9)

[1;43]

6 (7.2)

[1;19]

Disease duration of bronchiectasis at first follow up, years, mean (SD), [range]

6.4 (15.9)

[0;68]

7.5 (17.3)

[0;68]

1.7 (3.7)

[0;10]

  1. NA: not applicable
  2. Percentages are presented as % of available data